The global clinical trial imaging market size is expected to reach USD 1.91 billion by 2030, registering a CAGR of 7.8% from 2025 to 2030, according to a new report by Grand View Research, Inc. Increasing research and development spending to discover new drugs and therapies to treat chronic diseases is propelling the industry growth. Images obtained from the internal examination of the body are used to determine drug activity. Clinical trial imaging provides rapid, detailed, and accurate screening. The need for clinical trial imaging is rapidly increasing in all phases of trials. Medical imaging in clinical trials is used as a primary, quantitative, and surrogate biomarker.
The clinical trial design includes selecting patient population, stratification based on biomarkers, different methods for allocation treatments, choosing efficient and reliable endpoints and validation of surrogate endpoints, calculating sample size, trial simulations, adaptive trial set-up, statistical and interim analysis, and assisting clients to deal with regulatory authorities such as EMA and FDA to discuss study design or defend study results.
Market players provide analytical testing services, pharmacokinetic, reading, and pharmacodynamics services for enhanced clinical development. IXICO offers advanced technologies for catalyzing clinical trials in neuroscience. Imaging biomarkers by the company help in measuring the safety and effectiveness of therapies used for neuro-imaging. Imaging biomarkers are effective in radiological reads. This provides the reading of MRI scans for central neuro to enhance the assessment of ongoing monitoring of drug safety and subject eligibility
Request a free sample copy or view report summary: Clinical Trial Imaging Market Report
The reading and analytical services segment held the largest market share at 30.95% in 2024 and is expected to grow at a CAGR of 8.4% from 2025 to 2030, highlighting its critical role in ensuring the accuracy and reliability of imaging data in clinical research.
The biotechnology and pharmaceutical companies segment accounted for the largest share of 28.7% in 2024. The factor attributing to the dominance of this segment is the need to develop new drugs and therapies to cure chronic diseases.
Oncology segment held the largest market share of 23.63% in 2024. High prevalence of cancer cases and the constant need for new and innovative therapies to treat various types of cancer are expected to fuel the market growth.
The contract research organizations (CROs) segment is expected to grow significantly with a CAGR of 8.5% over the forecast period, owing to its essential role in developing new drugs and therapies for chronic diseases.
North America dominated the market with a revenue share of 47.93% in 2024 due to the increasing geriatric population, along with chronic diseases and growing demand for treatment options.
Grand View Research has segmented the global clinical trial imaging market based on modality, therapeutic area, services, end use and region:
Clinical Trial Imaging Modality Outlook (Revenue, USD Million, 2018 - 2030)
Computed Tomography Scan
Magnetic Resonance Imaging
X-Ray
Ultrasound
Optical Coherence Tomography (OCT)
Other Modalities
Clinical Trial Imaging Therapeutic Area Outlook (Revenue, USD Million, 2018 - 2030)
Neurovascular Diseases
Cardiovascular Diseases
Orthopedics & MSK Disorders
Oncology
Ophthalmology
Nephrology
Other Therapeutic Areas
Clinical Trial Imaging Services Outlook (Revenue, USD Million, 2018 - 2030)
Clinical Trial Design and Consultation Services
Reading and Analytical Services
Operational Imaging Services
System and Technology Support Services
Project and Data Management
Clinical Trial Imaging End Use Outlook (Revenue, USD Million, 2018 - 2030)
Biotechnology and Pharmaceutical Companies
Medical Devices Manufacturers
Academic and Government Research Institutes
Contract Research Organizations (CROs)
Other End Users
Clinical Trial Imaging Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Mexico
Europe
UK
Germany
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
India
China
Japan
Australia
Thailand
South Korea
Latin America
Brazil
Argentina
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait
List of Key Players in the Clinical Trial Imaging Market
IXICO plc
Navitas Life Sciences
Resonance Health
ProScan Imaging
Radiant Sage LLC
Medpace
Biomedical Systems Corp
Cardiovascular Imaging Technologies
Intrinsic Imaging
BioTelemetry
"The quality of research they have done for us has been excellent..."